The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation

Not Applicable

Terminated

Conditions: Head and Neck Cancer

Interventions: Behavioral: Yoga Video
Behavioral: Posture and Strengthening Video
Behavioral: Relaxation Video
Behavioral: Breath Work Video
Behavioral: Satisfaction Survey
Behavioral: Guided Yoga Session
Behavioral: Written Yoga Instructions

First Posted Date: 2019-10-31

Last Posted Date: 2020-10-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 19

Registration Number: NCT04146779

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Central Pain Syndrome in Survivors of Head and Neck Cancer

Not Applicable

Terminated

Conditions: Head and Neck Cancer

Interventions: Device: IPC-1000
Device: Magnetic resonance imaging
Other: Correlative Studies

First Posted Date: 2019-10-16

Last Posted Date: 2022-09-19

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 32

Registration Number: NCT04128267

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

Not Applicable

Terminated

Conditions: Neuroendocrine Tumor
Carcinoid Syndrome

Interventions: Dietary Supplement: Enterade®
Other: Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)

First Posted Date: 2019-08-28

Last Posted Date: 2021-05-21

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 11

Registration Number: NCT04073017

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

PCRC-Supported Legacy Intervention in Pediatric Palliative Care

Not Applicable

Completed

Conditions: Care Giver
Recurrent Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions: Other: Internet-Based Intervention
Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-08-16

Last Posted Date: 2023-11-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 300

Registration Number: NCT04059393

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Yoga Intervention in Supporting Children With Cancer and Their Parents During Chemotherapy Infusion

Not Applicable

Terminated

Conditions: Malignant Neoplasm

Interventions: Other: Questionnaire administration

First Posted Date: 2019-07-26

Last Posted Date: 2020-07-24

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 10

Registration Number: NCT04034914

Locations: 🇺🇸
Vanderbilt University School of Nursing, Nashville, Tennessee, United States

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia

Interventions: Drug: CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
Drug: IDH-1 Inhibitor FT-2102

First Posted Date: 2019-07-10

Last Posted Date: 2020-07-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT04013880

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Early Phase 1

Completed

Conditions: Estrogen Receptor-positive Breast Cancer

Interventions: Dietary Supplement: 2-Week Ketogenic Diet
Drug: Letrozole

First Posted Date: 2019-05-24

Last Posted Date: 2024-10-11

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 31

Registration Number: NCT03962647

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

Recruiting

Conditions: Cancer Survivor
Biological Sibling
Retinoblastoma
Intraocular Retinoblastoma
Unilateral Retinoblastoma

Interventions: Procedure: Biospecimen collection
Other: Vision assessment
Other: Questionnaire administration
Other: Quality of life assessment
Other: Laboratory Biomarker Analysis

First Posted Date: 2019-05-01

Last Posted Date: 2024-11-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 900

Registration Number: NCT03932786

Locations: 🇺🇸
University of Minnesoa, Minneapolis, Minnesota, United States
🇺🇸
Texas Childeren's Hospital, Houston, Texas, United States
🇺🇸
Washington School of Medicine at St. Louis, Saint Louis, Missouri, United States

and more 8 locations

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Phase 1

Terminated

Conditions: Ovarian Clear Cell Adenocarcinoma
Recurrent Endometrial Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
High Grade Fallopian Tube Serous Adenocarcinoma
High Grade Ovarian Serous Adenocarcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma

Interventions: Drug: Entinostat
Drug: Olaparib

First Posted Date: 2019-04-23

Last Posted Date: 2022-04-04

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 3

Registration Number: NCT03924245

Locations: 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents

Not Applicable

Completed

Conditions: Advanced Cancer
Relapsed Cancer
Refractory Cancer

Interventions: Behavioral: Animal-Assisted Interactions

First Posted Date: 2018-12-05

Last Posted Date: 2023-01-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 70

Registration Number: NCT03765099

Locations: 🇺🇸
Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy